Rigel Pharmaceuticals, Inc. (RIGL)
| Market Cap | 559.69M +59.0% |
| Revenue (ttm) | 299.77M +47.6% |
| Net Income | 364.23M +879.7% |
| EPS | 18.95 +809.5% |
| Shares Out | 18.50M |
| PE Ratio | 1.60 |
| Forward PE | 7.76 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 230,364 |
| Open | 30.56 |
| Previous Close | 30.30 |
| Day's Range | 29.99 - 31.09 |
| 52-Week Range | 18.14 - 52.24 |
| Beta | 1.18 |
| Analysts | Buy |
| Price Target | 53.20 (+75.87%) |
| Earnings Date | May 5, 2026 |
About RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test;... [Read more]
Financial Performance
In 2025, Rigel Pharmaceuticals's revenue was $294.28 million, an increase of 64.15% compared to the previous year's $179.28 million. Earnings were $367.02 million, an increase of 1999.08%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for RIGL stock is "Buy." The 12-month stock price target is $53.2, which is an increase of 75.87% from the latest price.
News
Rigel Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
The company outlined a transformational growth strategy, highlighted by the upcoming launch of VEPPANU, a first-in-class PROTAC for metastatic breast cancer, and strong commercial performance from its existing portfolio. R289 for lower-risk MDS shows promising early results, and financial discipline supports continued expansion.
Rigel to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announ...
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO ® (pralsetinib) as first-line treatment in patients with RET fusion-positive NS...
Rigel Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026
A four-pillar growth strategy has driven strong revenue and product expansion, highlighted by the in-licensing of VEPPANU, a first-in-class PROTAC for metastatic breast cancer. Profitability was achieved in Q3 2024, with further growth expected from new launches and pipeline advancements.
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 14, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announ...
Rigel Pharmaceuticals price target raised to $81 from $69 at Citi
Citi raised the firm’s price target on Rigel Pharmaceuticals (RIGL) to $81 from $69 and keeps a Buy rating on the shares. The firm views the in-licensing of Veppanu as…
H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’
After Rigel Pharmaceuticals (RIGL) announced it has entered into an exclusive global licensing agreement with Pfizer (PFE) and Arvinas (ARVN) for Veppanu for the treatment of ER+/HER2-, ESR1-mutated a...
Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu
Arvinas (ARVN) and Pfizer (PFE) have entered into a license agreement with Rigel Pharmaceuticals (RIGL) for the exclusive global development, manufacturing, and commercialization rights for Veppanu. V...
Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer
Rigel Pharmaceuticals (RIGL) announced that it has entered into an exclusive, global license agreement with Arvinas (ARVN) and Pfizer (PFE), subject to regulatory clearance, to develop, manufacture an...
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug
Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently approved breast cancer drug, marking Rigel's fourth commercial product on the market.
Rigel Pharmaceuticals Transcript: Investor update
VEPPANU, a newly FDA-approved PROTAC for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, is expected to become the largest product in the portfolio, supported by strong clinical data and a $1B+ U.S. market opportunity. The company is prepared for a rapid launch, leveraging its commercial expertise and infrastructure.
Rigel Pharmaceuticals Press release: Investor update
Rigel Pharmaceuticals issued a press release on May 12, 2026, disclosing material business information to investors.
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
VEPPANU has a novel mechanism of action, is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated...
Rigel Pharmaceuticals Slides: Corporate presentation
Rigel Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Rigel Pharmaceuticals price target lowered to $69 from $71 at Citi
Citi lowered the firm’s price target on Rigel Pharmaceuticals (RIGL) to $69 from $71 and keeps a Buy rating on the shares.
Rigel Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 26% year-over-year net product sales growth, led by TAVALISSE and REZLIDHIA, with total revenue reaching $58.8 million. The company reaffirmed 2026 guidance and advanced its R289 clinical program, while restructuring debt and regaining rights to the RIPK1 asset.
Rigel Pharmaceuticals Quarterly report: Q1 2026
Rigel Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 5, 2026.
Rigel Pharmaceuticals Earnings release: Q1 2026
Rigel Pharmaceuticals released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Rigel Pharmaceuticals Slides: Q1 2026
Rigel Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Rigel Pharmaceuticals reports Q1 EPS 44c, consensus 87c
Reports Q1 revenue $58.8M, consensus $ 62.4M. “Rigel entered 2026 with continued year-over-year growth from our commercial portfolio and financial discipline, driving another quarter of profitability....
Rigel Reports First Quarter 2026 Financial Results
First quarter 2026 total revenues of $58.8 million, including net product sales of $54.9 million and contract revenues from collaborations of $3.9 million Generated $8.7 million of net income in the f...
Rigel Pharmaceuticals Slides: Corporate presentation
Rigel Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., April 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2026 financial results after market close o...
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. I...
Rigel Pharmaceuticals Proxy statement: Proxy filing
Rigel Pharmaceuticals filed a proxy statement on April 3, 2026, providing details for shareholder voting and corporate governance matters.